Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

作者：Xiaowen Tang, Lin Yang, Zheng Li, Ansel P. Nalin, Haiping Dai, Ting Xu, Jia Yin, Fengtao You, Mingqing Zhu, Wenhong Shen, Guanghua Chen, Xiaming Zhu, Depei Wu, Jianhua Yu · 发表于：PubMed · 年份：2018 · 被引用次数：412 · 研究领域：CAR-T cell therapy research、Immune Cell Function and Interaction、Virus-based gene therapy research

(5 billion) cells per patient, no significant adverse effects were observed. CAR NK-92 cells can be produced at much lower cost compared to CAR T cells, and we believe after being optimized, they will be widely accessible for the treatment of cancer.